Obsidian Therapeutics

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform.  Vertex is also offering up to $1.3 billion in milestone payments in the deal, which will focus on using small-molecule compounds to “fine tune” the effects of …

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance Read More »

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies …

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies Read More »

Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions

Vertex Pharmaceuticals is collaborating with Obsidian Therapeutics to develop up to five new gene editing therapies. Obsidian’s technology precisely controls protein expression, a capability the partners plan to apply to several undisclosed serious diseases.